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  T
he creation and promotion of 
“female sexual dysfunction” 
(FSD) is a textbook case 
of disease mongering by the 
pharmaceutical industry and by other 
agents of medicalization, such as health 
and science journalists, healthcare 
professionals, public relations and 
advertising ﬁ  rms, contract research 
organizations, and others in the 
“medicalization industry.” Whether 
one relies on Lynn Payer’s original 
deﬁ  nition of disease mongering 
(“trying to convince essentially well 
people that they are sick, or slightly 
sick people that they are very ill” [1]), 
her checklist (Box 1), or the analysis 
of our pill-popping society that was 
recently offered by Greg Critser [2], 
the sequence of events and cast of 
participants involved in FSD matches 
the classic disease-mongering tactics 
[1,2]. 
    Each physical condition or life 
event that has been subject to disease-
mongering tactics has its own unique 
history. Sexual life has become 
vulnerable to disease mongering for 
two main reasons. First, a long history 
of social and political control of 
sexual expression created reservoirs 
of shame and ignorance that make 
it difﬁ  cult for many people to 
understand sexual satisfaction or cope 
with sexual problems in rational ways. 
Second, popular culture has greatly 
inﬂ  ated public expectations about 
sexual function and the importance 
of sex to personal and relationship 
satisfaction. 
    Thus the public is led to want and 
expect high rewards from sexual 
life without having tools to achieve 
these rewards. People fed a myth that 
sex is “natural”—that is, a matter of 
automatic and unlearned biological 
function—at the same time as they 
expect high levels of performance and 
enduring pleasure, are likely to look 
for simple solutions. This sets the stage 
for disease mongering, a process that 
encourages the conversion of socially 
created anxiety into medical diagnoses 
suitable for pharmacological treatment.
    In this essay, I begin by examining 
sexual attitudes in the 20th century that 
were crucial in setting the scene for the 
creation of FSD. I then highlight key 
steps in the history of FSD and of the 
campaign to challenge its reductionist 
approach to women’s sexual problems.
    Setting the Scene: Sex and the 
20th Century
    In the early 20th century, sexual life and 
interest were stimulated by intensive 
urbanization and immigration that 
disrupted old community-based patterns 
of sexual regulation [3,4]. Sexual 
choices and expectations, however, 
were still largely governed by traditional 
religion and a double standard. Public 
discourse around sex was moralistic, 
and sex-education materials were 
limited and stigmatized. By mid-century, 
surveys showed wide variation in sexual 
habits, with behavior patterns related to 
social class, gender, cohort, and other 
background factors [5]. 
    Dramatic liberalization occurred 
after World War II as purity campaigns 
failed to hold back the sex-promoting 
impact of changes in longevity, leisure, 
employment and childrearing, new 
technology, and mass media [4]. 
Effective oral contraceptives and 
medical treatments for venereal 
diseases removed sexual inhibitions 
due to fear of pregnancy and disease. 
A youth culture of charged eroticism 
developed. Changes in obscenity laws 
permitted sexual explicitness in the 
mass media. The women’s and gay- 
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  Box 1. The Major Disease-
Mongering Tactics Identiﬁ  ed by 
Lynn Payer [1] 
    1. “Taking a normal function and 
implying that there’s something wrong 
with it and it should be treated” (p. 88)
    2. “Imputing suffering that isn’t 
necessarily there” (p. 89)
  3.  “Deﬁ  ning as large a proportion of the 
population as possible as suffering 
from the ‘disease’” (p. 89)
  4.  “Deﬁ  ning a [condition] as a deﬁ  ciency 
disease or disease of hormonal 
imbalance” (p. 93)
    5. “Getting the right spin doctors” (p. 93)
    6. “Framing the issues in a particular way” 
(p. 94)
    7. “Selective use of statistics to 
exaggerate the beneﬁ  ts of treatment” 
(p. 95)
    8. “Using the wrong end point” (p. 96)
    9. “Promoting technology as risk-free 
magic” (p. 96)
    10. “Taking a common symptom that 
could mean anything and making 
it sound as if it is a sign of a serious 
disease” (p. 98) PLoS Medicine  |  www.plosmedicine.org 0437
and lesbian-rights movements of the 
1960s and 1970s raised the importance 
of sexual behavior and identity. Each 
new technological development in 
communications—movies, car radios, 
television, videotapes, Internet—was 
used to promote sex-related products 
and to escalate the importance of 
sexual life and the availability of 
stimulation.
  Medicalizing  Sexuality
    Beginning in the 1970s, along with 
the increasing sexual explicitness 
in popular culture, there were two 
competing academic theories of 
sexuality. In the social sciences and 
humanities, a social-constructionist 
perspective emphasized political, 
economic, and social determinants 
of sexual life [6]. It tended to see 
learning and education as keys to 
sexual satisfaction. In psychology and 
medicine, by contrast, a reductionist 
view of sexuality prevailed that stressed 
universal, evolution-based patterns of 
sexual motive, attraction, and conduct. 
This view saw satisfaction as an inherent 
result of normal function. In truth, 
however, there wasn’t much academic 
sex research of any sort, as the topic was 
controversial and hence underfunded. 
There were very few academic or 
professional training programs, and 
sexological organizations, conferences, 
and journals were lively but small and 
somewhat defensive, rather than parts 
of an established specialty area of 
sexuality studies.
    In the 1980s, the nature of sex 
research and expertise began to shift 
as a new “sexual medicine” focused 
on function was created by urologists, 
insurance reimbursement programs, 
diagnostic technologies, science and 
medicine journalists, and, then, the 
pharmaceutical industry [7]. 
    Urologists looked to new 
opportunities in genitourinary sexual 
medicine as their surgical careers were 
limited by the new (1984) kidney stone 
lithotripsy and by effective medications 
for benign prostate disease. Insurance-
based reimbursement for sex-problem 
treatments (including psychotherapy) 
became linked to a diagnostic 
classiﬁ  cation system that recognized 
only discrete sexual “dysfunctions” 
such as low desire, inadequate 
arousal/erection, and premature 
or delayed orgasm/ejaculation. 
Technologies for measuring genital 
blood ﬂ  ow and nerve function were 
widely used to substantiate dysfunction 
diagnoses. Taking advantage of 
post-1980s deregulatory policies, the 
pharmaceutical industry began to 
redirect its pipeline to new “lifestyle 
drugs” and its marketing to consumer 
advertising. Science and medicine 
journalists played key roles in whetting 
the public’s appetite for medical news 
about sex by breathlessly covering each 
new discovery and treatment. 
    In the 1980s and 1990s, urologists 
created organizations, journals, and 
“sexual health clinics” that focused on 
men’s erection problems. In 1992, a US 
National Institutes of Health consensus 
conference on “impotence” legitimized 
this work. Its outcome was a 34-page 
document that mentioned factors 
involved in etiology, maintenance, and 
treatment such as culture, partners, 
and sexual techniques, but, for the 
most part, it reiﬁ  ed “erection” as the 
essence of men’s sexuality, and called 
for new treatments and vastly expanded 
research into physiological details 
and treatments [8]. The creation of 
“erectile dysfunction” as a serious, 
prevalent, and treatable medical 
disorder was ﬁ  rmly in place by the time 
Viagra was launched in 1998 with an 
unprecedented global public-relations 
campaign, as Joel Lexchin describes in 
this issue of   PLoS Medicine   [9]. 
  Creating  FSD
    Although journalists began calling 
for a “female Viagra” only days after 
the March 1998 US Food and Drug 
Administration (FDA) approval of 
Viagra (examples of journalists’ calling 
DOI: 10.1371/journal.pmed.0030178.g001
  Figure 1.   Timeline for the Promotion of FSD from 1997 to Present
      AUA, American Urological Association; CME, Continuing Medical Education; JAMA, Journal of the 
American Medical Association
  (Figure:  Rusty  Howson) 
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for a “pink Viagra” are collected on 
http:⁄⁄www.fsd-alert.org/press.html), 
it was far from clear what medical 
condition Viagra was supposed to treat 
in women. Urologists had used the 
term “female sexual dysfunction” as 
early as 1997, referring to aspects of 
genital pathophysiology that might be 
akin to erectile dysfunction. Figure 1 
offers a timeline of events shaping the 
creation and promotion of FSD, from 
1997 to the present. 
    A May 1997 Cape Cod conference, 
“Sexual Function Assessment in 
Clinical Trials,” which was sponsored 
by pharmaceutical companies, was a 
watershed moment in the FSD story 
[10]. These companies bypassed 
existing sexology organizations and 
their annual conferences to convene 
an invitation-only industry–sexologist 
get-together. Papers and discussion 
were published in a special supplement 
to the   International Journal of Impotence 
Research   [10]. Signiﬁ  cantly, the 
introduction stated:
    “In the area of female sexual dysfunc-
tion, there is widespread lack of agree-
ment about the deﬁ  nition of sexual 
dysfunction, its pathophysiology or 
clinical manifestations, and the opti-
mal approach for research or clinical 
assessment (p. S1).”
    Deﬁ  nitional issues have plagued 
the FSD literature ever since, despite 
repeated industry-supported attempts 
to draw a bright line between healthy 
sexual function and medical disorder. 
The quest for a valid and reliable FSD 
assessment instrument has become a 
small growth industry in and of itself. 
    For the ﬁ  rst few years, the key players 
in the medicalization of women’s 
sexual problems were a small group 
of urologists who capitalized on their 
relationships with industry and recruited 
many sex researchers and therapists 
as allies. Irwin Goldstein of Boston 
University, an active erectile dysfunction 
researcher, opened the ﬁ  rst Women’s 
Sexual Health clinic in 1998 [11]. 
He convened the ﬁ  rst conference on 
female sexual function (called “New 
Perspectives in the Management of 
Female Sexual Dysfunction”) in October 
1999 in Boston. Goldstein is the editor 
of a journal that launched in 2004—the 
  Journal of Sexual Medicine   (http:⁄⁄jsm.
issir.org)—which has already published 
an industry-supported supplement on 
FSD [12].
    Jennifer Berman, Goldstein’s urology 
trainee at Boston University, together 
with her sister, sex educator Laura 
Berman, became the female face of 
FSD, opening a clinic at University 
of California Los Angeles (UCLA) in 
2001, and continuing to popularize 
FSD and off-label drug treatments on 
their television program, Web site, and 
books; in appearances on the television 
show “Oprah”; and in innumerable 
women’s magazines [13]. The UCLA 
clinic was closed in 2005, as both 
Jennifer (in Los Angeles, California) 
and Laura (now in Chicago, Illinois) 
opened fee-for-service women’s sexual-
health centers that offered medical 
assessments and treatments plus spa 
and yoga services [13]. Laura will also 
have her own reality TV sex-advice show 
later in 2006 (http:⁄⁄www.sho.com/
site/announcements/051005sexual.
do). One clear future angle to the 
FSD story will be its intersection with 
the new “holistic” and “boutique” 
(specialized, retainer, or cash-paying) 
medical trends as well as with drug-
friendly celebrity experts.
    Pﬁ  zer, the world’s largest 
pharmaceutical company, was the main 
promoter of FSD from 1997 to 2004, 
when its quest to have Viagra approved 
to treat “female sexual arousal 
disorder” ended because of consistently 
poor clinical-trial results. In its public 
statement, Pﬁ  zer said that that several 
large-scale, placebo-controlled studies 
including about 3,000 women with 
female sexual arousal disorder showed 
inconclusive results on the efﬁ  cacy of 
the drug [14]. Commenting on these 
trial results on Viagra, John Bancroft, 
director of the Kinsey Institute, told 
the   BMJ  : “The recent history of the 
study of female sexual dysfunction is a 
classic example of starting with some 
preconceived, and non-evidence based 
diagnostic categorisation for women’s 
sexual dysfunctions, based on the male 
model, and then requiring further 
research to be based on that structure. 
Increasingly it is becoming evident 
that women’s sexual problems are not 
usefully conceptualised in that way” 
[14]. Nevertheless, Viagra (and the 
idea that it   must   work for women) has 
DOI: 10.1371/journal.pmed.0030178.g002 
  Figure 2.   Timeline of Events Beginning in 1999 of Activism, Which Came to Be Called the 
“Campaign for a New View of Women’s Sexual Problems”
   (Figure:  Rusty  Howson) 
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been so successfully branded that it 
continues to be prescribed off-label for 
women [15]. 
    Next in line with a potential drug 
for FSD has been Procter & Gamble 
(P&G), the multibillion-dollar soap, 
shampoo, and snack company that 
makes only ﬁ  ve prescription drugs [16]. 
P&G’s 2004 annual report states that its 
drug risedronate (Actonel, approved in 
1998 for Paget disease and in 2000 for 
osteoporosis), “became a billion-dollar 
brand faster than any other brand in 
P&G history” [17]. Perhaps encouraged 
by this success in selling medicine to 
women, P&G had begun investing 
heavily in a testosterone patch (brand 
name Intrinsa) to treat “hypoactive 
sexual desire disorder.” The unnoticed 
shift in 2004 in FSD identity and 
promotion from female sexual arousal 
disorder to hypoactive sexual desire 
disorder is another hallmark moment 
in the FSD story, illustrating how the 
effort to match up some drug with 
FSD moved freely among symptoms 
and labels. P&G’s trials with Intrinsa 
got many gynecologists and their 
organizations heavily involved in the 
new sexual pharma–medicine for the 
ﬁ  rst time. Unfortunately for the drug 
company, an FDA advisory panel voted 
unanimously not to approve Intrinsa, 
saying that P&G had not provided 
sufﬁ  cient long-term safety data and 
questioning the clinical signiﬁ  cance 
of the Intrinsa trials [18]. However, 
testosterone researcher Jan Shifren 
estimates that one-ﬁ  fth of all the 
prescriptions of testosterone products 
approved for men are actually written 
(off-label) for women [19]. 
     By 2006, FSD has become a medical 
and media reality, despite the obvious 
ongoing difﬁ  culties in deﬁ  ning the 
condition and in getting a drug 
approved. Disease mongering has led 
to the successful “branding” of FSD.
  Activist  Response
    In 1999, I became concerned that 
the imminent inaugural Boston 
conference on FSD would represent 
only the reductionist view of women’s 
sexual problems and would likely 
ignore the fundamental political 
and interpersonal reality of women’s 
sexual lives. I had been employed as 
a research and clinical psychologist 
in urology departments from 1983 
to 1996, and I worried that the 
mechanistic view of sexuality I had seen 
applied to men’s sexual function would 
just be transposed to women. Viagra 
had just been approved, I knew about 
the Cape Cod conference, and I feared 
that urologists (with ﬁ  nancial backing 
from Pﬁ  zer) would use a conference on 
FSD to promote Viagra for women.
    Although I had no experience in 
organizing, I felt I had to take steps 
to make sure a space was created for 
diverse (i.e., not just medical) opinions 
about women’s sexual problems. I 
submitted a critical essay about the new 
FSD to a Boston feminist newsletter 
[20], and, with Carol Tavris, I wrote 
an op-ed for the   Los Angeles Times   [21]. 
Through Internet communication, I 
invited feminist critics of medicalization 
to meet with me in Boston and take 
some action at the FSD conference. 
Figure 2 offers a timeline, beginning 
in 1999, of the activism that came to be 
called the “Campaign for a New View of 
women’s sexual problems” [22].
    The campaign and its challenge 
to FSD disease mongering have had 
two crucial components [23]. The 
ﬁ  rst, a theoretical critique of the 
medical model of sexual problems, was 
developed in the New View Manifesto, 
books, articles, and lectures. The 
manifesto, now available in several 
languages [22], was authored by a 
group of feminist academics, activists, 
and clinicians calling themselves 
“The Working Group on a New View 
of Women’s Sexual Problems.” The 
second component of the campaign is 
pharma–watchdog activism, consisting 
of media interviews, conferences, FDA 
and professional presentations, and a 
Web site (http:⁄⁄fsd-alert.org). 
    The New View Manifesto focuses on 
weaknesses of the prevailing sexual 
dysfunction classiﬁ  cation and medical 
model. It promotes a politically 
sensitive social-constructionist 
perspective and recommends 
abandoning the effort to deﬁ  ne 
“normal” sexual function. It offers 
an alternative classiﬁ  cation system of 
causes for sexual problems rooted in 
society, relationships, psychology, and 
disease. The activism challenges claims 
made for each emerging FSD drug 
in terms based on recurring biases 
in clinical trials, dangers of off-label 
promotion, researchers’ conﬂ  icts of 
interest, and neglect of nonmedical 
theory and research on sexuality.
  Conclusion
    Sexual life and its pleasures, problems, 
and satisfactions are subject to 
changing demands and expectations. 
Recently, the pharmaceutical industry 
has taken an aggressive interest in 
sex, using public relations, direct-
to-consumer advertising, promotion 
of off-label prescribing, and other 
tactics to create a sense of widespread 
sexual inadequacy and interest in drug 
treatments. 
    The public ﬁ  nds medicalization 
attractive because the notion of simple 
but scientiﬁ  c solutions ﬁ  ts in with 
a general cultural overinvestment 
in biological explanations and 
interventions, and promises to bypass 
sexual embarrassment, ignorance, and 
anxiety. This wish will inevitably end 
in stories of personal disappointment, 
but media promotion, advertising 
hyperbole, and an active pipeline will 
create continuing hope for the next 
new drug along with a neglect of other 
models of sex and ways to deal with 
sexual discontent. 
    The New View Campaign to 
challenge the disease mongering of 
FSD can be seen as part of a widespread 
new arena of public-health advocacy 
that deals with corporate practices 
that affect health, such as those in 
the tobacco, automobile, and food 
industries [24]. Activism on behalf 
of women’s sexuality leads also to 
coalition with sexual-rights, sex-
education, and reproductive-rights 
organizations. It has taken the work 
of many public-spirited people and 
organizations to shed the necessary 
light on FSD disease mongering. But 
the difﬁ  culties the industry and its 
experts continue to have in nailing 
down FSD testify to some small success 
on our part.   
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